KPRX Quote, Financials, Valuation and Earnings

Electromed, Inc. has a net margin of 84.08% compared to Kiora Pharmaceuticals, Inc.'s net margin of 12.65%. Kiora Pharmaceuticals, Inc.'s return on equity of -34.44% beat Electromed, Inc.'s return on equity of 18.89%.

Kiora Pharmaceuticals, Inc. has a consensus price target of $11.00, signalling upside risk potential of 458.38%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 26.32%. Given that Kiora Pharmaceuticals, Inc. has higher upside potential than Electromed, Inc., analysts believe Kiora Pharmaceuticals, Inc. is more attractive than Electromed, Inc..

Kiora Pharmaceuticals, Inc. has a beta of -0.753, which suggesting that the stock is 175.254% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.

Kiora Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiora Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Kiora Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. Kiora Pharmaceuticals, Inc.'s net income of $26.8K is lower than Electromed, Inc.'s net income of $2.1M. Notably, Kiora Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 30.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiora Pharmaceuticals, Inc. is -- versus 3.80x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Myomo, Inc. has a net margin of 84.08% compared to Kiora Pharmaceuticals, Inc.'s net margin of -36.3%. Kiora Pharmaceuticals, Inc.'s return on equity of -34.44% beat Myomo, Inc.'s return on equity of -68.35%.

Kiora Pharmaceuticals, Inc. has a consensus price target of $11.00, signalling upside risk potential of 458.38%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 390.2%. Given that Kiora Pharmaceuticals, Inc. has higher upside potential than Myomo, Inc., analysts believe Kiora Pharmaceuticals, Inc. is more attractive than Myomo, Inc..

Kiora Pharmaceuticals, Inc. has a beta of -0.753, which suggesting that the stock is 175.254% less volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.583%.

Kiora Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiora Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.

Kiora Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Myomo, Inc. quarterly revenues of $10.1M. Kiora Pharmaceuticals, Inc.'s net income of $26.8K is higher than Myomo, Inc.'s net income of -$3.7M. Notably, Kiora Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiora Pharmaceuticals, Inc. is -- versus 1.00x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of 84.08% compared to Kiora Pharmaceuticals, Inc.'s net margin of -862.39%. Kiora Pharmaceuticals, Inc.'s return on equity of -34.44% beat VolitionRX Ltd.'s return on equity of --.

Kiora Pharmaceuticals, Inc. has a consensus price target of $11.00, signalling upside risk potential of 458.38%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 780%. Given that VolitionRX Ltd. has higher upside potential than Kiora Pharmaceuticals, Inc., analysts believe VolitionRX Ltd. is more attractive than Kiora Pharmaceuticals, Inc..

Kiora Pharmaceuticals, Inc. has a beta of -0.753, which suggesting that the stock is 175.254% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

Kiora Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiora Pharmaceuticals, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Kiora Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than VolitionRX Ltd. quarterly revenues of $627.3K. Kiora Pharmaceuticals, Inc.'s net income of $26.8K is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, Kiora Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiora Pharmaceuticals, Inc. is -- versus 17.13x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of 84.08% compared to Kiora Pharmaceuticals, Inc.'s net margin of 3.93%. Kiora Pharmaceuticals, Inc.'s return on equity of -34.44% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Kiora Pharmaceuticals, Inc. has a consensus price target of $11.00, signalling upside risk potential of 458.38%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 93.3%. Given that Kiora Pharmaceuticals, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Kiora Pharmaceuticals, Inc. is more attractive than Xtant Medical Holdings, Inc..

Kiora Pharmaceuticals, Inc. has a beta of -0.753, which suggesting that the stock is 175.254% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Kiora Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiora Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Kiora Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Kiora Pharmaceuticals, Inc.'s net income of $26.8K is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Kiora Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 76.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiora Pharmaceuticals, Inc. is -- versus 0.85x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.